Adults first followed a low-calorie diet, and those who lost at least 5% of their weight, 422 people, were then assigned to liraglutide or placebo for 56 weeks, with diet and exercise counseling throughout. On liraglutide they lost a further 6.2%; on placebo, 0.2%. It was published in the International Journal of Obesity in 2013.1
How the trial was run
Participants were adults with a body mass index of 30 or more, or 27 or more with related conditions. During the low-calorie diet run-in they lost 6.0% of their screening weight on average. Diet and exercise counseling continued for everyone after the run-in, on the drug and on placebo alike. Only those who reached 5% went on to the randomized part, so the trial asked a narrower question than most weight trials: not whether the drug produces weight loss, but whether it holds and extends a loss already made.1
The trial had three main outcomes: the percentage change in weight from the point of randomization, the share who kept the full 5% run-in loss, and the share who lost a further 5%.1
What it found
- From randomization to week 56, weight fell by a further 6.2% on liraglutide and 0.2% on placebo, a difference of 6.1 percentage points.
- The 5% run-in loss was kept by 81.4% on liraglutide and 48.9% on placebo.
- A further loss of 5% or more was reached by 50.5% on liraglutide and 21.8% on placebo.
- Liraglutide produced small improvements in several heart and metabolic risk factors.
Wadden et al., 2013. A further 5% or more was lost by 50.5% on liraglutide and 21.8% on placebo.1
The Saxenda label includes this trial as its Study 3 and, with its own counting, reports a further loss of 4.9% on liraglutide while weight on placebo rose by 0.3%.2 Both accounts describe the same people; the gap comes from how missing data were handled. The label's table starts from an average weight of about 100 kg at randomization. A further loss of at least 5% was reached by 44.2% on liraglutide against 21.7% on placebo, and of more than 10% by 25.4% against 6.9%.2
What it means
About half of the people on placebo could not hold on to the 5% they had lost by dieting, even with continued counseling; on liraglutide four in five did. The authors' conclusion was that liraglutide, with diet and exercise, maintained the diet-induced loss and added to it over 56 weeks.1 Tirzepatide was later tested the same way, after an intensive lifestyle program, in SURMOUNT-3, where people lost a further 18.4% on the drug while those on placebo regained 2.5%.3
The two trials make the same point from different decades: a diet can start the loss, and a medicine of this class can hold it and add to it, while the placebo groups drift back. Our page on what to eat on a GLP-1 covers the diet side of treatment.
For anyone planning to diet first and add a medicine later, the trial gives a useful benchmark: a 5% loss from diet alone was kept by only about half of those who received no drug.1
Side effects
Stomach and gut complaints were reported more often on liraglutide than on placebo, but most were short-lived and mild or moderate.1 On Saxenda across its trials, nausea was reported by 39.3% against 13.8% on placebo.2 Our page on nausea on a GLP-1 covers what helps.
Limits
The trial enrolled only people who succeeded with the diet, so it says nothing about those who could not lose 5% that way. It lasted 56 weeks after the run-in, so it cannot show how long the benefit lasts, and it is registered as NCT00781937.1
Sources
- Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37:1443-1451. doi:10.1038/ijo.2013.120
- SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published June 15, 2026; sections 6.1 and 14. dailymed.nlm.nih.gov
- Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29:2909-2918. doi:10.1038/s41591-023-02597-w
Related analyses
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
Zepbound plateau: when weight loss slows, why, and what the trials show
Nausea on a GLP-1: how common, how long, when it peaks and what helps
How much protein to eat on Zepbound or Wegovy: the targets, calculated for your weight
Log meals and weight together and see what keeps the scale steady for you.
Open Dose Insider